Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Iterum Therapeutics Plc shares valued at $35,000 were purchased by Dunne Michael W. on Dec 22 ’23. At $1.40 per share, Dunne Michael W. acquired 25,000 shares. The insider’s holdings grew to 113,754 shares worth approximately $0.21 million following the completion of this transaction.
Also, Dunne Michael W. purchased 10,000 shares, netting a total of over 18,442 in proceeds. Following the buying of shares at $1.84 each, the insider now holds 88,754 shares.
Before that, Dunne Michael W. had added 20,000 shares to its account. In a trade valued at $40,690, the Director bought Iterum Therapeutics Plc shares for $2.03 each. Upon closing the transaction, the insider’s holdings increased to 20,000 shares, worth approximately $0.15 million.
As published in a research note from Gabelli & Co on May 28, 2021, Iterum Therapeutics Plc [ITRM] has been rated up from a Sell to a Hold. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid March. As of June 02, 2020, RBC Capital Mkts has decreased its “an Outperform” rating to a “Sector perform” for ITRM. Earlier on January 21, 2020, Gabelli & Co downgraded its rating. Their new recommendation was “a Sell” for ITRM stock which previously was a “a Buy”.
Analyzing ITRM Stock Performance
During the last five days, there has been a surge of approximately 17.61%. Over the course of the year, Iterum Therapeutics Plc shares have dropped approximately -5.08%. Shares of the company reached a 52-week high of $2.3400 on 01/30/24 and a 52-week low of $1.2197 on 02/23/24. A 50-day SMA is recorded $1.5275, while a 200-day SMA reached $1.2661. Nevertheless, trading volume fell to 0.75 million shares from 88100.0 shares the previous day.
Support And Resistance Levels for Iterum Therapeutics Plc (ITRM)
According to the 24-hour chart, there is a support level at 1.6633, which, if violated, would cause prices to drop to 1.4565. In the upper region, resistance lies at 2.0034. The next price resistance is at 2.1367. RSI (Relative Strength Index) is 65.55 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0733, which suggests the price will decrease in the coming days. Percent R is at 11.54%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Iterum Therapeutics Plc subject to short interest?
Stocks of Iterum Therapeutics Plc saw a sharp rise in short interest on Mar 15, 2024 jumping by 40000.0 shares to 1.21 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 1.17 million shares. A jump of 3.31% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.63 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.63.
